194 related articles for article (PubMed ID: 12747873)
1. Enfuvirtide, a new drug for HIV infection.
Fletcher CV
Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873
[No Abstract] [Full Text] [Related]
2. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
[TBL] [Abstract][Full Text] [Related]
3. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
Pham PA
Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
[No Abstract] [Full Text] [Related]
4. Enfuvirtide approved for defusing HIV.
Burton A
Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
[No Abstract] [Full Text] [Related]
5. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.
Zhang X; Lin T; Bertasso A; Evans C; Dorr A; Kolis SJ; Salgo M; Patel I;
J Clin Pharmacol; 2007 Apr; 47(4):510-7. PubMed ID: 17389560
[TBL] [Abstract][Full Text] [Related]
6. Enfuvirtide: antiretroviral class 4, drug 1.
Asboe D
HIV Clin Trials; 2004; 5(1):1-6. PubMed ID: 15002081
[TBL] [Abstract][Full Text] [Related]
7. [Enfuvirtide: first drug of a new family of antiretroviral agents].
Espona M; Ferrández O; Grau S; Carmona A
Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
[TBL] [Abstract][Full Text] [Related]
8. Enfuvirtide for prophylaxis against HIV Infection.
Ferranti S; Menichetti F
N Engl J Med; 2003 Aug; 349(8):815. PubMed ID: 12930939
[No Abstract] [Full Text] [Related]
9. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
[TBL] [Abstract][Full Text] [Related]
10. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
11. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin.
Price RW; Parham R; Kroll JL; Wring SA; Baker B; Sailstad J; Hoh R; Liegler T; Spudich S; Kuritzkes DR; Deeks SG
Antivir Ther; 2008; 13(3):369-74. PubMed ID: 18572749
[TBL] [Abstract][Full Text] [Related]
12. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
13. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Loutfy MR; Raboud JM; Montaner JS; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme ZL; Mo T; Gough K; Rachlis A; Harrigan PR; Walmsley SL
Antiviral Res; 2007 Jul; 75(1):58-63. PubMed ID: 17196268
[TBL] [Abstract][Full Text] [Related]
14. Enfuvirtide doubles chances for suppression.
AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
[No Abstract] [Full Text] [Related]
15. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Cooper DA; Lange JM
Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
[TBL] [Abstract][Full Text] [Related]
16. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
Morse C; Maldarelli F
J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
[No Abstract] [Full Text] [Related]
17. Formal approval for Fuzeon.
AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
[No Abstract] [Full Text] [Related]
18. [Enfuvirtide. Two injections per day for HIV].
Taéron C
Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
[No Abstract] [Full Text] [Related]
19. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
[TBL] [Abstract][Full Text] [Related]
20. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
Schäfer B
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
[No Abstract] [Full Text] [Related]
[Next] [New Search]
